Based on these results, reducing TLR4/MyD88 pathway signaling in cardiomyocytes by reducing gut-derived LPS levels is one of the key mechanisms by which myricetin affects DCM. The gene discussed is TLR4; the disease is familial dilated cardiomyopathy.